MA, NY, RI and WA consistently saw big drops in sales after states banned sales of flavored e-cigs

More and more localities and states have stopped waiting for the FDA to get rid of flavored e-cigarettes, including menthol, and enacted local laws or policies ending the sale of flavored e-cigarettes. (Others, led by San Francisco, have banned the sale of all flavored tobacco products.) Fatma Ali and colleagues at the CDC Foundation, CDCContinue reading “MA, NY, RI and WA consistently saw big drops in sales after states banned sales of flavored e-cigs”

Ecig enthusiasts respond to criticism that they selectively cited the science by ignoring the conclusions of the papers they do cite

In addition to the excellent paper by Samet and Barrington-Trimis the American Journal of Public Health recently published two letters to the editor — one from Wasim Maziak and one from me — criticizing the paper “Balancing consideration of the risks and benefits of e-cigarettes.” That paper argues that concerns over youth e-cigarette use needsContinue reading “Ecig enthusiasts respond to criticism that they selectively cited the science by ignoring the conclusions of the papers they do cite”

E-cigs: What about helping the smokers?

A lot of the discussion of e-cigarettes has been about the millions of youth who are starting nicotine addiction with them. While the tobacco companies are obvious beneficiaries of this fact, no one — not even the companies — publicly claims that this is a good thing. The goal is to “help addicted smokers quitContinue reading “E-cigs: What about helping the smokers?”

Industry easily adapts to FDA’s limited action on e-cig flavors

In response to skyrocketing youth e-cigarette use, driven largely by Juul removable pod flavored e-cigs, in January 2020, FDA said they would “prioritize enforcement” against most flavored pod e-cigs. Not surprisingly, youth and young adults have shifted to menthol and disposable flavored e-cigs that FDA is not prioritizing. Now Shivani Gaiha and her colleagues atContinue reading “Industry easily adapts to FDA’s limited action on e-cig flavors”

FDA can and should prioritize youth over Juul and other e-cigs sales while it ponders the long term

After years of delays and deadline extensions that allowed thousands of e-cigarettes to remain on the market without any FDA premarket review and millions of kids to become nicotine addicts, health groups successfully sued FDA to force action. As a result, on July 11, 2019 Judge Paul Grimm ordered FDA to require premarket tobacco product applications (PMTAs) forContinue reading “FDA can and should prioritize youth over Juul and other e-cigs sales while it ponders the long term”

IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on these risks, so FDA should not issue an exposure modification MRTP order for IQOS 3

My colleagues and I at the UCSF TCORS submitted this public comment to the FDA. The Regulations.gov tracking number is kt4-u9mw-wc65. A PDF version is available here. IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on theseContinue reading “IQOS emissions create risks of immunosuppression and pulmonary toxicity and the supplemental modified risk tobacco product application for IQOS 3 does not address new published research on these risks, so FDA should not issue an exposure modification MRTP order for IQOS 3”

FDA’s recent press release raises 3 issues on how CTP is judging e-cigs

On August 26, 2021, FDA denied marketing orders for around 55,000 flavored e-cigarettes because the manufacturers had not made the case that authorizing the sale of these products was “appropriate for the protection of public health,” the standard in the 2009 Family Smoking Prevention and Tobacco Control Act that gave the FDA jurisdiction over tobaccoContinue reading “FDA’s recent press release raises 3 issues on how CTP is judging e-cigs”

Long-established science supports maintaining and expanding smokefree casinos and other environments

While all commercial gaming in Atlantic City, Michigan and Pennsylvania were temporarily smokefree for a period of time because of the COVID-19 pandemic, smoking has resumed as mask mandates have expired. They did so despite the fact that the science on secondhand smoke has been well-accepted for a long time. The casinos have been encouragedContinue reading “Long-established science supports maintaining and expanding smokefree casinos and other environments”

New WHO report highlights falling cigarette use and challenges that new tobacco products pose to public health and implementation of the FCTC

On July 27, 2021 the WHO released the WHO report on the global tobacco epidemic 2021: addressing new and emerging products, its eighth such report. The good news is that it documents solid progress in reducing tobacco use. After over a century of growth, “between 2007 and 2019, smoking rates decreased from a global averageContinue reading “New WHO report highlights falling cigarette use and challenges that new tobacco products pose to public health and implementation of the FCTC”

CDC’s new mask guidance and why FDA CTP should not assume e-cigs help smokers quit in the real world

On May 13, 2021 the CDC lifted most restrictions on the use of masks for people fully vaccinated against COVID-19 (two weeks after the second shot for Pfizer or Moderna and 1 week after J&J). While some people thought this was a political decision, CDC Director Walensky explained in detail that real world experience showedContinue reading “CDC’s new mask guidance and why FDA CTP should not assume e-cigs help smokers quit in the real world”